Scripps Genomic Medicine

The R&D deal targets oncology and cardiovascular disease.

The study, which surveyed more than 2,000 people, found that the "results of a direct-to-consumer genomic risk test do not affect health-related behavior."

A survey primarily using Scripps employees and Navigenics test offering shows that 50 percent of DTC genomics test takers have concerns, but over 80 percent want to know risks even of non-preventable diseases.

"We are concentrating on two initial areas — diabetes and aging research," Eric Topol, chief academic officer of Scripps Health, said. "Diabetes PGx work is of vital interest to Scripps, Sanofi, and the public."

Under terms of the alliance, a Sanofi-aventis Group subsidiary will fund each year up to three Discovery Innovation Grants intended to offer flexible financing for innovative research proposals from investigators at a division of Scripps Health.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.